Results 1 to 5 of 5
Page 1 of 1
TypeTitleAuthor(s)YearViews
76 week follow up of HBeAg-positive chronic hepatitis B patients treated with telbivudine, adefovir or switched from adefovir to telbivudineMarcellin, P; Chan, HLY; Lai, CL; Cho, M; Moon, YM; Chao, YC; Heathcote, J; Myers, R; Harb, G; Brown, NA2007117
 
In hepatitis B patients treated with either adefovir or telbivudine, maximal early hbv suppression at 24 weeks predicts optimal one-year efficacyMarcellin, P; Chan, HLY; Lai, CL; Clio, M; Heathcote, I; Moon, YM; Chao, YC; Myers, R; Harb, G; Brown, NA200794
 
A Randomized Trial of Telbivudine (LdT) vs Adefovir for HBeAg-positive Chronic Hepatitis B: Final Week 52 resultsBzowej, N; Chan, HLY; Lai, CL; Cho, M; Moon, YM; Chao, YC; Heathcote, EJ; Myers, R; Minuk, G; Marcellin, P; Jeffers, L; Sievert, W; Kaiser, R; Harb, G; Chao, GC; Brown, NA2006162
 
A Randomized Trial of Telbivudine (LdT) vs Adefovir for HBeAg-positive Chronic Hepatitis B: Results of the Primary Week 24 AnalysisHeathcote, EJ; Chan, HL; Cho, M; Lai, CL; Moon, YM; Chao, YC; Myers, R; Minuk, G; Marcellin, P; Jeffers, L; Sievert, W; Kaiser, R; Chao, G; Brown, N2006110
 
A randomized trial of telbivudine (LDT) vs. adefovir for HBeAg-positive chronic hepatitis B: Results of the primary week 24 analysisChan, HLY; Lai, CL; Cho, M; Heathcote, J; Moon, Y-M; Chao, Y-C; Myers, R; Minuk, G; Marcellin, P; Jeffers, L; Sievert, W; Kaiser, R; Chao, G; Brown, N2006117
 
Page 1 of 1
Export Records
Step 1: Select content and export format
  • Citation only
Step 2: Select export method
  • Download